Pfizer Inc. and BioNTech SE announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved their supplemental Biologics License Application for a new monovalent COVID-19 vaccine, COMIRNATY LP.8.1, targeting adults aged 65 and older and individuals aged 5 to 64 with underlying conditions that increase their risk of severe COVID-19 outcomes. The approval covers the LP.8.1-adapted vaccine, designed to address evolving SARS-CoV-2 sublineages. The FDA’s decision follows a rev...